ESMO Preview: Cancer Stocks to Watch
BOSTON ( TheStreet) -- A key European cancer drug research meeting -- the 35th European Society for Medical Oncology (ESMO) Congress -- kicks off Friday in Milan and will include key data presentations from the following companies:
Indication: Prostate cancer
Presentation date: Sat. Oct. 9
The Provenge data from four double-blind, placebo-controlled studies is not new, but this is the first time Dendreon will present Provenge efficacy and safety data to a European medical audience. Provenge is not approved in Europe. Dendreon is expected to make its European regulatory plans public later this year or early next year.
Indication: Ovarian cancer
Presentation: Sat. Oct. 9
Indication: Breast cancer
Presentation: Sun. Oct. 10 Interim results will be presented from an open-label phase II study of TDM-1 compared against Herceptin plus taxotere in front-line metastatic breast cancer. These data are important because it will provide the first (early) clue about TDM-1's ability to eventually replace Herceptin as the front-line drug treatment of choice for women newly diagnosed with metastatic Her-2 positive breast cancer. Johnson & Johnson (JNJ)
Indication: Prostate cancer
Presentation date: Monday, Oct. 11 J&J announced in September that treatment with abiraterone helps men with advanced, metastatic prostate cancer live longer, but the details -- how big is that survival benefit? -- was not disclosed. Researchers at ESMO will present the full data from the abiraterone phase III study, which enrolled metastatic prostate cancer patients previously treated with chemotherapy. Seattle Genetics (SGEN)
Indication: Non-Hodgkin lymphoma and kidney cancer
Presentation: Mon. Oct. 11 Early, phase I data on SGN-75, another "armed antibody" drug candidates in Seattle Genetics' cancer drug pipeline. These data are from a dose escalation study enrolling patients with relapses refractory NHL or metastatic kidney cancer.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV